Overview

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Patients With Rheumatoid Arthritis With Ongoing Treatment With Methotrexate

Status:
Completed

Trial end date:
2005-08-01

Target enrollment:

Participant gender:

Summary

This study assessed the long-term safety and tolerability of ACZ885 in patients with rheumatoid arthritis, as well as long-term efficacy, long-term preservation and/or improvement of joint structure and bone mineral density, and long term maintenance of health-related quality of life.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Novartis

Treatments:

Antibodies, Monoclonal
Methotrexate